Tests lurbinectedin in people with high-grade pancreatic neuroendocrine tumors
Tests lurbinectedin as a later treatment for high-grade pancreatic neuroendocrine tumors.
Key facts
- Who runs it
- National Cancer Center, Korea
- Where
- Goyang-si, South KoreaSee the site
- Trial code
- Registry title
- Patients With High-grade Pancreatic Neuroendocrine Tumors
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 46 people, planned
- Started
- 23 Sept 2025
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Treatments tested
- Lurbinectedin 4 MG Injection [Zepzelca]
- Record updated
- 1 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a pancreatic neuroendocrine tumor or carcinoma whose earlier standard cancer treatment did not work. It tests lurbinectedin as second-line treatment.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Pancreatic neuroendocrine tumor or neuroendocrine carcinoma (high-grade).
- Earlier treatment
- Earlier standard anti-cancer treatment must have failed.
Main reasons for not taking part
- Being treated for another cancer (unless treatment ended and no disease for at least 2 years)
- Pregnant or breastfeeding women
- The investigator judges the person unsuitable for medical reasons
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Clinical diagnosis of Pancreatic neuroendocrine tumor or neuroendocrine carcinoma
- Documented failure of prior standard anti-cancer treatment
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³
- Platelet count ≥ 100,000 cells/mm³
- Ability to understand study content, willingness to comply with study procedures, and commitment to complete the study
Who cannot take part
- Currently receiving treatment for other cancers (except those who completed treatment and have been disease-free for at least 2 years prior to enrollment)
- Pregnant or breastfeeding women
- Deemed unsuitable for participation by the investigator due to clinical or medical reasons
Where in South Korea
- National Cancer CenterGoyang-si, South KoreaEnrolling by invitation
About the trial
What the trial wants to find out
* Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic chemotherapy is essential in cases with grade 3 pNETs or pNECs. * Cisplatin/etoposide remains the treatment of choice for high-grade pNET/pNEC. Other irinotecan-based therapies, such as FOLFIRI (cisplatin/irinotecan), FOLFOX, and temozolomide ± capecitabine, have been employed; however, a standard of care remains to be established.
The group in the trial
- single armTreatment being tested
Lurbinectedin shall be administered intravenously at a dose of 3.2 mg/m2 over 60 minutes every 21 days. The administration of the study drug shall be continued until disease progression or the occurrence of unacceptable toxicity.
Treatment: Lurbinectedin 4 MG Injection [Zepzelca]
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Lurbinectedin as a Second-line Treatment for High-grade Pancreatic Neuroendocrine Tumors
- Plain-language title
- Tests lurbinectedin in people with high-grade pancreatic neuroendocrine tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 October 2025